文献速递其他结缔组织病

一项多国调查:了解临床医生对系统性硬化症患者使用质子泵抑制剂的看法

A multi-national survey to identify clinicians' perspectives concerning Proton Pump inhibitors in patients with systemic sclerosis.
PubMed 文献 · Semin Arthritis Rheum · 2024-02-23

通过国际医生网络和社交媒体邀请参与照护系统性硬化症(SSc)患者的临床医生填写在线调查,共评估来自36个国家的227份回复。多数医生认为胃食管反流病是SSc致病和致死的重要原因,但仅约半数认为有确凿证据支持质子泵抑制剂(PPIs)在SSc中的疗效。PPIs常用于有症状或客观证据的胃食管反流病,长期安全性存在差异化的担忧。

要点

  • 227名来自36个国家的临床医生参与了关于SSc患者PPIs处方的在线调查。

核心结论

  • PPIs在SSc中经常被处方,副作用是公认的担忧,尤其是长期治疗。
  • 对难治性胃食管反流病的手术干预态度存在显著差异。
  • 亟需针对SSc中PPIs的未来研究和实用治疗推荐。

研究设计与样本

  • 通过国际医生网络和社交媒体邀请参与照护SSc患者的临床医生参与在线调查。
  • 共评估来自36个国家的227名临床医生的回复。

主要发现

  • 41.4%的医生同意、45.4%的医生强烈同意胃食管反流病是SSc致病和致死的重要原因。
  • 仅16%的医生认为生活方式调整有效。
  • 43%的医生同意、11%的医生强烈同意有确凿证据支持PPIs在SSc中的疗效。
  • 处方PPIs最常见的原因包括:对生活方式调整无反应的有症状胃食管反流病(95%)、胃食管反流病的客观证据(82%)、声音嘶哑或呼吸道症状(71%)。
  • 对PPIs长期安全性担忧程度(0-10分,10为非常担忧)最高的三项平均分为:小肠细菌过度生长(5.5)、骨质疏松(5.4)、药物相互作用(5.2)。

关键数值与推荐

  • 调查中医生对胃食管反流病是SSc致病和致死重要原因的同意程度:同意41.4%,强烈同意45.4%。
  • 调查中医生对有确凿证据支持PPIs在SSc中疗效的同意程度:同意43%,强烈同意11%。
  • 处方PPIs最常见原因的比例:对生活方式调整无反应的有症状胃食管反流病95%,胃食管反流病客观证据82%,声音嘶哑或呼吸道症状71%。
  • 对PPIs长期安全性担忧程度(0-10分)平均分:小肠细菌过度生长5.5,骨质疏松5.4,药物相互作用5.2。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Proton Pump Inhibitors (PPIs) are widely used in SSc for gastroesophageal reflux disease (GERD). However, there is little evidence to support their empirical use and long-term safety has been questioned. Our objective was to better describe clinicians' attitudes toward PPIs prescription and use in SSc patients. METHODS: Clinicians involved in the care of SSc patients were invited through international physician networks and social media to participate in an online survey. RESULTS: Responses from 227 clinicians from 36 countries were evaluable. The majority 'agreed' (41.4 %) or 'strongly agreed' (45.4 %) that GERD is a major cause of morbidity in SSc. Lifestyle modifications are seldom (16 %) considered effective. Only half 'agreed' (43 %) or 'strongly agreed' (11 %) there is solid evidence supporting PPIs efficacy in SSc. The most common reasons for PPIs prescription were symptomatic GERD unresponsive to lifestyle modification (95 %), objective evidence of GERD (82 %), and hoarseness or respiratory symptoms (71 %). There are variable concerns about PPIs long-term safety in SSc. The three highest (mean) reasons (0-10, here 10 is 'very concerned') were: small intestinal bacterial overgrowth (5.5), osteoporosis (5.4), and drug interactions (5.2). There are significant differences in attitudes towards surgery for refractory GERD, and concerns about potential complications. PPIs may have a putative role for disease modification (e.g., ILD and calcinosis), and the role of immunosuppression is uncertain for GI (gastrointestinal) disease in SSc. CONCLUSION: PPIs are frequently prescribed in SSc. Side effects are a recognized concern, especially regarding long-term therapy. There is significant variation in attitudes towards surgical intervention. Future research and practical treatment recommendation for PPIs in SSc are urgently needed.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Bandini G, Alunno A, Oliveira Pinheiro F, et al. A multi-national survey to identify clinicians' perspectives concerning Proton Pump inhibitors in patients with systemic sclerosis. Semin Arthritis Rheum. 2024. PMID: 38430623. doi:10.1016/j.semarthrit.2024.152419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。